Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2022

Attention-deficit-hyperactivity disorder (ADHD) is one of the most common childhood disorders that can continue into adulthood. For decades, childhood ADHD has been treated primarily with CNS stimulants. In the United States, although numerous convenient, once-daily, long-acting CNS stimulants in various distinct formulations are available, they are classified as controlled substances, and abuse liability with these agents is a concern. As a result, nonstimulant therapies (e.g., atomoxetine, guanfacine ER) have become key therapeutic alternatives, though a lingering perception of less robust efficacy versus CNS stimulants had led to the continued strong presence of CNS stimulants in the treatment algorithm for childhood ADHD.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed childhood ADHD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed childhood ADHD patients?
• How have branded drugs (e.g., Vyvanse) been integrated into the treatment algorithm, and what is their source of business?
• What percentage of childhood ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of childhood ADHD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients with childhood ADHD?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs: Atomoxetine (Strattera, generics), Adzenys XR-ODT, Daytrana, Evekeo, guanfacine ER (Intuniv, generics), Jornay PM, methylphenidate CR (Concerta, generics), methylphenidate SR/ER (Ritalin LA, generics), mixed amphetamine salts (Adderall XR, generics), Mydayis, Quillichew ER, Vyvanse, Vyvanse Chewable, etc.

Key analysis provided:

• Brand use across longitudinal patient sample.
• Newly diagnosed patient analysis.
• Treatment initiation and progression.
• Line of therapy analysis.
• Combination therapy analysis.
• Source of business for recently treated patients.
• Persistency and compliance analysis.
• Product-level patient flowcharts.

Solution Enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.